The Recombinant Erythropoietin Market set for robust growth driven by increasing use of biosimilars by 2031

The recombinant erythropoietin market deals with use of biosimilar medicines for treatment of anemia and blood related disorders. Recombinant erythropoietin is a man-made form of endogenous protein hormone erythropoietin that stimulates bone marrow to produce red blood cells. It is used to treat anemia in patients with chronic kidney disease, cancer, HIV/AIDS and chemotherapy induced anemia. Recombinant erythropoietin reduces need for blood transfusions and improves quality of life. The global recombinant erythropoietin market is estimated to be valued at US$ 459.3 Mn in 2024 and is expected to exhibit a CAGR of 7.9% over the forecast period 2024 to 2031.

Get More Insights Recombinant Erythropoietin Market

https://articlescad.com/re...